Copyright
©The Author(s) 2023.
World J Clin Cases. Nov 6, 2023; 11(31): 7629-7634
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7629
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7629
Table 1 Summary of previous case reports of multi-targeted tyrosine kinase inhibitor induced hyperammonemic encephalopathy, n (%)
| Sex | Female/Male, (n) | 5/6 |
| Age | Median (range), yr | 47 (20-74) |
| Diagnosis (n) | GIST | 5 (45) |
| CRC | 2 (18) | |
| RCC | 2 (18) | |
| BC | 1 (9) | |
| pNET | 1 (9) | |
| Drug (n) | Sunitinib | 6 (55) |
| Regorafenib | 4 (36) | |
| Pazopanib | 1 (9) | |
| Ammonia level | Median (range), μmoL/L | 151 (87-278) |
| Time to symptom | Median (range), d | 17 (1-390) |
| Time to recovery | Median (range), d | 3 (1-12) |
- Citation: Hayakawa T, Funakoshi S, Hamamoto Y, Hirata K, Kanai T. Sunitinib-induced hyperammonemic encephalopathy in metastatic gastrointestinal stromal tumors: A case report. World J Clin Cases 2023; 11(31): 7629-7634
- URL: https://www.wjgnet.com/2307-8960/full/v11/i31/7629.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i31.7629